Granzyme K+ CD8 T cells slow tauopathy progression by targeting microglia

Hannah D Mason1, Yvonne L Latour1, Christopher T Boughter2

  • 1Viral Immunology and Intravital Imaging Section, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA.

Nature Immunology
|June 24, 2025
PubMed

Insights

Beneficial immune cells called granzyme K (GZMK)+ CD8+ T cells slow neurodegenerative tauopathy by targeting distressed microglia. These cells are crucial for controlling phosphorylated tau (pTau) spread and neurological decline.

Area of Science:

  • Immunology
  • Neuroscience
  • Cell Biology

Background:

  • Neurodegenerative diseases involve complex immune responses.
  • Understanding beneficial immune mechanisms in tauopathy is critical.

Purpose of the Study:

  • To identify beneficial immune pressures during tauopathy development in mice and humans.
  • To investigate the role of CD8+ T cells in tauopathy progression.

Main Methods:

  • Utilized mice expressing mutant human tau.
  • Analyzed microglia and CD8+ T cell interactions.
  • Examined human brain lesions from various neurodegenerative conditions.
  • Investigated the impact of immune checkpoint blockade (TIGIT, PD-1) and CD8+ T cell deletion.

Main Results:

  • Microglia initially slowed tauopathy by controlling phosphorylated tau (pTau) spread.
  • Over time, microglia became distressed antigen-presenting cells targeted by CD8+ T cells.
  • CD8+ T cells expressing granzyme K (GZMK) deposited GZMK onto microglia.
  • Immune checkpoint blockade (TIGIT, PD-1) worsened disease progression.
  • GZMK+ CD8+ T cells were found in human tauopathy lesions.
  • CD8+ T cell deletion accelerated pTau spread and neurological decline.

Conclusions:

  • GZMK+ CD8+ T cells are a key feature of tauopathy.
  • These T cells play a protective role by targeting distressed microglia.
  • Targeting GZMK+ CD8+ T cells may offer a therapeutic strategy for tauopathies.